Lexington-based T2 Biosystems made waves in the diagnostics industry in 2014 when the FDA approved its test for sepsis, a complication of infections that is one of the leading causes of death in the U.S. The product, called the T2Candida Panel, can diagnose sepsis in a matter of hours, compared to traditional blood cultures that can take up to six days.
T2 (Nasdaq: TTOO) took another major step forward on Monday when it announced that it had formally asked the FDA to approve a similar product, called…
Lexington-based T2 Biosystems made waves in the diagnostics industry in 2014 when the FDA approved its test for sepsis, a complication of infections that is one of the leading causes of death in the U.S. The product, called the T2Candida Panel, can diagnose sepsis in a matter of hours, compared to traditional blood cultures that can take up to six days.
T2 (Nasdaq: TTOO) took another major step forward on Monday when it announced that it had formally asked the FDA to approve a similar product, called…